ArticleBMC women's health2026
Long-term efficacy of uterine artery embolization for adenomyosis and analysis of prognostic factors: a cohort study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the long-term therapeutic efficacy of uterine artery embolization (UAE) for adenomyosis and to identify independent prognostic factors associated with postoperative recurrence.
methodsA total of 200 adenomyosis patients who underwent UAE were retrospectively included and categorized into a non-recurrence group and a recurrence group. Baseline characteristics, symptom improvement, and postoperative complications were compared between groups. Recurrence-free survival was assessed using the Kaplan–Meier method. Univariable and multivariable Cox proportional hazards regression analyses were performed to determine independent predictors of recurrence.
resultsPatients in the recurrence group were younger, had a longer disease duration, more severe preoperative symptoms, and higher carbohydrate antigen 125 (CA-125) levels. They also had higher proportions of diffuse-type adenomyosis, thicker junctional zones, and more sparsely vascularized lesions. The non-recurrence group showed greater improvement in pain, pictorial blood loss assessment chart (PBAC) scores, and quality of life. The incidence of postoperative complications was higher in the recurrence group (P = 0.024). Kaplan–Meier analysis showed recurrence-free survival rates of 90% at 12 months and approximately 69% at 24 months after UAE. Age (hazard ratio [HR] = 0.903, P = 0.008), junctional zone thickness (HR = 1.333, P < 0.001), and preoperative CA-125 level (HR = 1.029, P < 0.001) were independent prognostic factors.
conclusionUAE significantly improves symptoms in patients with adenomyosis, with relatively stable efficacy during the first postoperative year, although the risk of recurrence increases thereafter. Younger age, increased junctional zone thickness, and elevated preoperative carbohydrate antigen 125 levels may assist in preoperative risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.